Shuang Guo | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Shuang Guo | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Dr Shuang Guo, Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital: Beijing Tsinghua Changgung Hospital, China

Dr. Shuang Guo is a dedicated postdoctoral researcher at Beijing Tsinghua Changgung Hospital, affiliated with the School of Clinical Medicine at Tsinghua University. With a Ph.D. in Clinical Medicine from the prestigious Huazhong University of Science and Technology, Dr. Guo has contributed significantly to the field of cardiovascular and genetic diseases. Her multidisciplinary research approach bridges clinical practice with cutting-edge molecular science, emphasizing hereditary arrhythmias, hypertension, and vascular disorders. Dr. Guo has published influential articles in international journals and is actively involved in innovation, holding several patents related to vascular health and gastrointestinal treatments. As a passionate investigator and co-developer of novel diagnostic and therapeutic strategies, she consistently pushes the boundaries of translational medicine. Dr. Guo’s dedication to scientific excellence and patient-centered research continues to enhance understanding and treatment of complex hereditary and vascular diseases in China and beyond.

Publication Profile

orcid

Education 

Dr. Shuang Guo earned her Ph.D. in Clinical Medicine from the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, one of China’s top institutions in medical education and biomedical research. During her doctoral training, she cultivated a solid foundation in cardiovascular pathology, molecular diagnostics, and translational medicine. Her academic journey was marked by hands-on clinical exposure combined with deep exploration of hereditary diseases, enabling her to integrate lab-based discoveries with bedside care. The program offered her robust mentorship and multidisciplinary collaboration opportunities that enhanced her clinical insight and research acumen. This rigorous educational experience provided the basis for her continued research excellence and led directly to her postdoctoral appointment at Tsinghua University. Her academic background also includes comprehensive training in medical genetics, vascular physiology, and clinical trial design, which continues to inform her postdoctoral investigations into novel treatments and personalized care for cardiovascular and hereditary disorders.

Experience

Currently serving as a postdoctoral researcher at Beijing Tsinghua Changgung Hospital, affiliated with the School of Clinical Medicine, Tsinghua University, Dr. Shuang Guo focuses on vascular biology, hereditary cardiovascular diseases, and precision medicine. Her postdoctoral work includes conducting high-impact research, co-authoring clinical trials, and filing patents on molecular therapies for gastrointestinal and vascular diseases. She collaborates with a multidisciplinary team of clinicians, biologists, and bioengineers to translate laboratory findings into therapeutic solutions. Before her postdoc, she gained extensive research experience at Huazhong University of Science and Technology, where she contributed to translational cardiovascular studies and clinical case analyses at Union Hospital. Dr. Guo is also actively engaged in manuscript writing, grant applications, and patent development, underscoring her commitment to innovation and collaboration. Her professional journey demonstrates a strong intersection of research excellence and clinical relevance, with a focus on improving diagnostic and therapeutic outcomes in genetically mediated and vascular-related conditions.

Awards and Honors

While specific named awards are not listed, Dr. Shuang Guo’s contributions to the medical and scientific community are demonstrated through her leadership as first author in multiple peer-reviewed journals, co-first authorship in a major JACC publication, and her involvement in five innovative patents related to gastrointestinal and vascular health. Her research has garnered recognition in respected publications such as Genes, Journal of Vascular Surgery, and JACC: Basic to Translational Science, reflecting high scholarly merit. These achievements speak to her excellence in both foundational research and applied clinical studies. Dr. Guo’s role in inventing novel uses of inulin, identifying mutation genes associated with hypercholesterolemia, and contributing to the development of therapeutic applications for short-chain fatty acids highlights her contribution to innovation. Her growing reputation in cardiovascular and hereditary disease research underscores her role as a rising scientific leader. Future recognition is likely as her contributions continue to impact global healthcare.

Research Focus

Dr. Shuang Guo’s research is rooted in clinical and molecular investigation of hereditary cardiovascular and gastrointestinal diseases. Her primary focus areas include genetic arrhythmias, monogenic hypertension, vascular inflammation, and abdominal aortic aneurysms. She is particularly interested in translational research—bridging the gap between genetic findings and clinical applications. Her work explores the therapeutic potential of dietary fibers like inulin and microbiota-derived short-chain fatty acids in modulating immune responses and vascular health. Dr. Guo’s ongoing studies involve identifying novel genetic mutations linked to hypercholesterolemia and other inherited conditions. She applies molecular biology, clinical diagnostics, and bioinformatics to uncover mechanisms underlying disease progression. Her research also emphasizes the role of immune modulation in disease treatment, especially via regulatory T-cell activity in vascular disorders. Through multidisciplinary collaboration, she aims to develop minimally invasive strategies and precision-based therapies to improve patient care, focusing on personalized medicine in complex, genetically-influenced disease models.

Publication Top Notes

  • 📘 Pathogenesis and Clinical Characteristics of Hereditary Arrhythmia DiseasesGenes, 2024.

  • 📗 Selective Minimally Invasive Strategy for Acute Superior Mesenteric Artery ObstructionJournal of Vascular Surgery, 2025.

  • 📙 Propionate Alleviates Abdominal Aortic Aneurysm by Modulating Colonic Regulatory T-Cell Expansion and RecirculationJACC: Basic to Translational Science, 2022.

  • 📕 Research Advances in Monogenic Inherited Hypertension中国医学前沿杂志(电子版), 2024

Salma Abdelnasser | Life Sciences | Best Researcher Award

Dr. Salma Abdelnasser | Life Sciences | Best Researcher Award

Researcher at National Research Centre, Egypt

Dr. Salma Abdelnasser is an accomplished researcher with a PhD in Microbiology from Ain Shams University, Cairo, Egypt. Her expertise lies in the production and characterization of novel marine bacterial exopolysaccharides and their therapeutic potential, particularly in the context of cancer treatment. She has extensive technical skills, including the isolation and purification of bacterial strains, RNA isolation, real-time PCR, and advanced data analysis. Dr. Abdelnasser has held various positions at the National Research Center (NRC) in Cairo, ranging from Research Specialist to her current role as a Researcher. She has led significant research projects, including studies on the role of miRNAs and exopolysaccharides in hepatocellular carcinoma, and the purification and characterization of marine bacterial exopolysaccharides. Her research has been published in reputable journals, reflecting her contributions to the field of microbial biotechnology and cancer therapeutics.

Professional Profiles:

📚 Education:

Dr. Salma Abdelnasser is an accomplished academic with a Doctor of Philosophy in Science (PhD) specializing in Microbiology from the Faculty of Science at Ain Shams University in Cairo, Egypt. Her doctoral research focused on the “Production of Novel Marine Bacterial Exopolysaccharides: Their Effect on Immunological Response and Apoptotic Pathways for Hepatocellular Carcinoma.” This thesis explored innovative approaches in microbiology, examining how marine bacterial exopolysaccharides can influence immune responses and apoptotic mechanisms in the context of liver cancer.

Professional Experience:

Dr. Salma Abdelnasser has held several key positions in the Microbial Biotechnology Department, Genetic Engineering & Biotechnology Division, at the National Research Center (NRC) in Cairo, Egypt. Since July 2018, she has been serving as a Researcher, where she continues to contribute to significant advancements in microbial biotechnology. Prior to this role, she was an Assistant Researcher from January 2016 to July 2018, demonstrating her growing expertise and dedication to her field. From August 2013 to January 2016, Dr. Abdelnasser worked as a Research Assistant, building her foundation in research methodologies and techniques. Her career at the NRC began as a Research Specialist, a position she held from January 2007 to August 2013. Throughout her tenure at the NRC, Dr. Abdelnasser has consistently shown a commitment to advancing genetic engineering and biotechnology.

Skills:

Dr. Salma Abdelnasser possesses a robust set of technical skills relevant to her field of expertise. She is proficient in the isolation and purification of bacterial strains from marine sediment through serial dilution and streak plate methods. Additionally, she has extensive experience in the production, isolation, and purification of bacterial exopolysaccharides (EPSs). Dr. Abdelnasser is skilled in identifying EPS-producing bacterial strains with high rates of cell death through 16S rRNA gene sequencing. She can assess the in vitro cytotoxicity of partially purified EPSs extracted from marine bacterial strains using in vitro cytotoxic assays. To confirm the proposed chemical structures of EPSs, she analyzes their infrared (IR) spectra, mass spectra, and high-performance liquid chromatography (HPLC) data. Dr. Abdelnasser is adept at isolating RNA and employing real-time PCR to assess the apoptotic activity of promising EPSs, followed by statistical analysis of the PCR data. Furthermore, she studies the pro-apoptotic effects of promising EPSs using the Human Apoptosis Antibody Array-Membrane (43 targets) ab134001 Kit (abcam® England) and is proficient in analyzing data from antibody arrays. These skills underscore Dr. Abdelnasser’s extensive expertise and capabilities in microbiological research and its applications.

Research:

Dr. Salma Abdelnasser has led several impactful research projects as a Principal Investigator. One of her notable projects is titled “Investigating the Role of miRNAs on Apoptotic and Angiogenic Pathways in Hepatocellular Carcinoma Cells Treated with Bacillus sonorensis Exopolysaccharide (EPS-1),” which runs from 2022 to 2024 and is funded by the National Research Centre, Giza, Egypt (grant number: 13060123). This study aims to explore the potential synergistic effects of miRNA and EPS-1 on pro-apoptotic and anti-angiogenic genes. Hybrid anticancer drugs are emerging as promising therapeutic options that can effectively address the limitations of conventional anticancer drugs. This project seeks to demonstrate the positive role of combining miRNA and EPS-1 in modulating key genes involved in the development, progression, and metastasis of hepatocellular carcinoma (HCC). Given that the expression of microRNAs is often altered in cancer cells, and that exopolysaccharides (EPSs) are gaining attention as a novel source for cancer treatment, this research holds significant potential for advancing cancer therapeutics.

 

📚Publications :

Publication: “Preventive potential of Bacillus sonorensis exopolysaccharide upon hepatocellular carcinoma and quantitation of tumor suppressor protein p53”

Authors: Abdelnasser, S.M., Ahmed, Y.M.

Journal: European Journal of Cancer Prevention

Year: 2022

Volume: 31(6), pp. 513–522

Citations: 0

Publication: “Human apoptosis antibody array-membranes studying the apoptotic effect of marine bacterial exopolysaccharides in HepG2 cells”

Authors: Abdelnasser, S., Yahya, S.M., Mohamed, W., Mahmoud, M., Asker, M.S.

Journal: Journal of Cancer Research and Therapeutics

Year: 2021

Volume: 17(1), pp. 38–45

Citations: 2

Publication: “Newly isolated marine bacterial exopolysaccharides enhance antitumor activity in HepG2 cells via affecting key apoptotic factors and activating toll-like receptors”

Authors: Yahya, S.M.M., Abdelnasser, S.M., Hamed, A.R., El Sayed, O.H., Asker, M.S.

Journal: Molecular Biology Reports

Year: 2019

Volume: 46(6), pp. 6231–6241

Citations: 17

Publication: “Antitumor exopolysaccharides derived from novel marine Bacillus: Isolation, characterization aspect and biological activity”

Authors: Abdelnasser, S.M., Yahya, S.M.M., Mohamed, W.F., Mahmoud, M.G., Gadallah, M.A.

Journal: Asian Pacific Journal of Cancer Prevention

Year: 2017

Volume: 18(7), pp. 1847–1854

Citations: 33

Publication: “Differential effects of c-myc and ABCB1 silencing on reversing drug resistance in HepG2/Dox cells”

Authors: Yahya, S.M.M., Hamed, A.R., Emara, M., Abd-Ellatef, G.E.F., Abdelnasser, S.M.

Journal: Tumor Biology

Year: 2016

Volume: 37(5), pp. 5925–5932

Citations: 8